Examkin

Question

Difficulty: HardDiagnostic Workup and Test Sequencing

A gastroenterology consultation is requested for a 42-year-old male who has developed severe, recurrent peptic ulcer disease despite strict adherence to maximal high-dose proton pump inhibitor therapy. He additionally reports a six-month history of high-volume, watery diarrhea that improves only slightly with fasting. A recent esophagogastroduodenoscopy demonstrated markedly hypertrophic gastric folds and multiple atypical ulcerations extending into the distal duodenum and proximal jejunum. Vital signs are stable: temperature 37.0°C (98.6°F), blood pressure 118/76 mmHg, pulse 74/min, and respiratory rate 14/min. Laboratory results reveal a normal basic metabolic panel, intact parathyroid hormone, and a serum calcium level of 9.2 mg/dL. The clinical team strongly suspects a functional neuroendocrine tumor and plans a comprehensive evaluation. Arrange the following diagnostic modalities in the correct, guideline-directed sequence, progressing from initial biochemical screening to precise anatomic localization.

  1. 1Measurement of fasting serum gastrin concentration and gastric pH
  2. 2Secretin stimulation test (for equivocal initial screening results)
  3. 3Somatostatin receptor positron emission tomography (PET)/CT scan
  4. 4Endoscopic ultrasound (EUS) for locoregional evaluation

Answer

The correct diagnostic sequence is: Measurement of fasting serum gastrin concentration and gastric pH -> Secretin stimulation test -> Somatostatin receptor PET/CT scan -> Endoscopic ultrasound (EUS).
The correct diagnostic sequence for a suspected gastrinoma strictly follows the core medical principle of biochemical confirmation prior to anatomic localization. The first step is documenting hypergastrinemia in an acidic gastric environment to exclude physiologic causes. Because mildly elevated gastrin levels can be equivocal, a secretin stimulation test is the next logical step to confirm autonomous, inappropriate gastrin secretion. Once biochemically confirmed, non-invasive whole-body imaging with a somatostatin receptor PET/CT is indicated to localize the primary tumor and identify metastases. Finally, if non-invasive imaging is negative or if precise locoregional staging is required for surgical enucleation, invasive endoscopic ultrasound is performed.

Step-by-Step Solution

1
Recognize the clinical syndrome requiring evaluation.
The presentation of refractory peptic ulcer disease in atypical locations combined with chronic secretory diarrhea is highly suggestive of Zollinger-Ellison syndrome (gastrinoma).
Identifying the specific functional neuroendocrine syndrome determines the correct targeted diagnostic pathway.
2
Select the most appropriate initial biochemical screening test.
Measurement of fasting serum gastrin concentration alongside gastric pH.
This establishes whether hypergastrinemia is present and confirms it is secondary to autonomous tumor secretion rather than an appropriate physiological response to achlorhydria.
3
Identify the confirmatory biochemical test.
Secretin stimulation test.
If the initial gastrin level is mildly to moderately elevated (equivocal), a secretin stimulation test is required to definitively confirm autonomous secretion, as secretin paradoxically increases gastrin levels in gastrinoma.
4
Establish the sequence for anatomic localization.
Non-invasive whole-body imaging (Somatostatin receptor PET/CT) followed by invasive regional imaging (EUS) if needed.
Guidelines mandate that biochemical confirmation must precede anatomic imaging. Once confirmed, non-invasive imaging evaluates the whole body for the primary tumor and metastases. EUS is reserved as a highly sensitive but invasive subsequent step for surgical planning or when non-invasive imaging is negative.

Key Concept

The sequential diagnostic evaluation of suspected Zollinger-Ellison syndrome progresses strictly from initial biochemical screening (fasting gastrin and gastric pH) to confirmatory provocation testing (secretin stimulation), followed by non-invasive functional localization (somatostatin receptor imaging), and finally invasive locoregional evaluation (endoscopic ultrasound).
Estimated Time:1m 30s
Rate this question

Topics

Diagnostic Workup and Test Sequencing

More questions from this topic